INT11488

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.57
First Reported 1992
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 15
Total Number 15
Disease Relevance 9.92
Pain Relevance 3.06

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

peptidase activity (KLK1) nucleus (KLK1)
Anatomy Link Frequency
plasma 2
cleavage 2
blood 1
bladder 1
KLK1 (Homo sapiens)
Pain Link Frequency Relevance Heat
bradykinin 128 99.92 Very High Very High Very High
antagonist 33 99.36 Very High Very High Very High
Pain 48 95.64 Very High Very High Very High
interstitial cystitis 6 93.40 High High
Inflammation 12 92.72 High High
vincristine 4 84.84 Quite High
headache 6 46.84 Quite Low
depression 6 46.44 Quite Low
b2 receptor 8 5.00 Very Low Very Low Very Low
Pain score 4 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Congenital Anomalies 1 99.40 Very High Very High Very High
Myocardial Infarction 3 99.24 Very High Very High Very High
Hereditary Angioedema 542 99.04 Very High Very High Very High
Pressure And Volume Under Development 153 97.80 Very High Very High Very High
Pain 39 95.64 Very High Very High Very High
Interstitial Cystitis 6 93.40 High High
INFLAMMATION 12 92.72 High High
Targeted Disruption 14 92.36 High High
Hemorrhage 4 90.64 High High
Hypertension 1 88.04 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Other treatments, such as kallikrein inhibitors and bradykinin antagonists, are unlikely to be effective for prophylaxis due to their short half-lives.
Negative_regulation (inhibitors) of kallikrein associated with antagonist and bradykinin
1) Confidence 0.57 Published 2010 Journal Allergy Asthma Clin Immunol Section Body Doc Link PMC2887436 Disease Relevance 0.21 Pain Relevance 0.18
Patients who underwent hydrodistention and subsequently experienced relief from the bladder symptoms had a decrease in urinary kallikrein levels, whereas patients who failed to improve following hydrodistention did not.
Negative_regulation (decrease) of kallikrein in bladder
2) Confidence 0.57 Published 1994 Journal J. Urol. Section Abstract Doc Link 8051740 Disease Relevance 0.81 Pain Relevance 0.65
Ecallantide is an inhibitor of the protein kallikrein and as of Nov 2009 has been approved for the use of acute attacks of HAE in the United States.
Negative_regulation (inhibitor) of kallikrein associated with hereditary angioedema
3) Confidence 0.57 Published 2010 Journal Allergy Asthma Clin Immunol Section Body Doc Link PMC2887436 Disease Relevance 1.01 Pain Relevance 0.12
Designed by phage display technology, DX-88 is a recombinant protein capable of binding to and inhibiting human kallikrein.
Negative_regulation (inhibiting) of kallikrein
4) Confidence 0.57 Published 2008 Journal Clin Mol Allergy Section Body Doc Link PMC2374835 Disease Relevance 0.62 Pain Relevance 0.13
Given its regulatory effects on kallikrein, C1-inhibtor might well have been designated "kallikrein inhibitor."


Negative_regulation (inhibitor) of kallikrein
5) Confidence 0.57 Published 2008 Journal Clin Mol Allergy Section Body Doc Link PMC2374835 Disease Relevance 0.44 Pain Relevance 0.15
Five new therapies are in Phase III clinical development: a kallikrein inhibitor (DX-88), a bradykinin receptor-2 antagonist (Icatibant), and three C1-inhibitor replacement therapies.
Negative_regulation (inhibitor) of kallikrein associated with antagonist and bradykinin
6) Confidence 0.42 Published 2008 Journal Clin Mol Allergy Section Body Doc Link PMC2374835 Disease Relevance 0.79 Pain Relevance 0.14
HAE is estimated to affect 10,000 people in the US and is caused by deficient or dysfunctional C1-inhibitor, a naturally occurring molecule that is known to inhibit kallikrein, bradykinin, and other serine proteases in plasma.
Negative_regulation (inhibit) of kallikrein in plasma associated with hereditary angioedema and bradykinin
7) Confidence 0.42 Published 2008 Journal Allergy Asthma Proc Section Abstract Doc Link 18387221 Disease Relevance 0.91 Pain Relevance 0.29
The other two agents, a kallikrein inhibitor and a bradykinin receptor-2 antagonist, target contact system components that are mediators of vascular permeability.
Negative_regulation (inhibitor) of kallikrein associated with antagonist and bradykinin
8) Confidence 0.42 Published 2008 Journal Clin Mol Allergy Section Abstract Doc Link PMC2374835 Disease Relevance 0.47 Pain Relevance 0.16
It is used to inhibit the formation of plasmin and fragments of the Hageman factor, leading to the inhibition of kallikrein and bradykinin production [10].
Negative_regulation (inhibition) of kallikrein associated with bradykinin
9) Confidence 0.41 Published 2010 Journal Allergy Asthma Clin Immunol Section Body Doc Link PMC2887436 Disease Relevance 1.03 Pain Relevance 0.12
Insufficient inhibition of kallikrein results in overproduction of bradykinin, and episodic swelling from excess local bradykinin[1].
Negative_regulation (inhibition) of kallikrein associated with pressure and volume under development and bradykinin
10) Confidence 0.41 Published 2010 Journal Allergy Asthma Clin Immunol Section Body Doc Link PMC2922091 Disease Relevance 0.53 Pain Relevance 0.14
By contrast, blood levels of kallidin, but not bradykinin, peptides were suppressed in patients with severe cardiac failure, suggesting that the activity of the tissue kallikrein-kinin system may be suppressed in this condition.
Negative_regulation (suppressed) of tissue kallikrein in blood associated with bradykinin and myocardial infarction
11) Confidence 0.41 Published 2000 Journal Braz. J. Med. Biol. Res. Section Abstract Doc Link 10829095 Disease Relevance 0.57 Pain Relevance 0.25
In dextran sulfate-activated plasma, Neurotropin inhibited the formation of BK, the cleavage of high molecular weight kininogen (HK) and the formation of kallikrein-C1 inhibitor and activated coagulation factor XII (FXIIa)-C1 inhibitor complexes.
Negative_regulation (inhibitor) of kallikrein-C1 in cleavage associated with bradykinin
12) Confidence 0.27 Published 1992 Journal Biochem. Pharmacol. Section Abstract Doc Link 1562287 Disease Relevance 0.44 Pain Relevance 0.29
In dextran sulfate-activated plasma, Neurotropin inhibited the formation of BK, the cleavage of high molecular weight kininogen (HK) and the formation of kallikrein-C1 inhibitor and activated coagulation factor XII (FXIIa)-C1 inhibitor complexes.
Negative_regulation (inhibitor) of kallikrein-C1 in cleavage associated with bradykinin
13) Confidence 0.19 Published 1992 Journal Biochem. Pharmacol. Section Abstract Doc Link 1562287 Disease Relevance 0.44 Pain Relevance 0.29
C1 inhibitor is the primary endogenous inhibitor of the kallikrein-kinin (contact) cascade.
Negative_regulation (inhibitor) of kallikrein-kinin
14) Confidence 0.06 Published 2007 Journal J. Allergy Clin. Immunol. Section Abstract Doc Link 17559913 Disease Relevance 0.72 Pain Relevance 0.14
The pathophysiologic basis of HAE was demonstrated to be a deficiency of C1INH in 1963 by Virginia Donaldson [1], clarifying the lack of kallikrein inhibitory activity in HAE patient plasma observed the year before by Landerman et al [25].
Negative_regulation (lack) of kallikrein in plasma associated with hereditary angioedema
15) Confidence 0.01 Published 2010 Journal Allergy Asthma Clin Immunol Section Body Doc Link PMC2921104 Disease Relevance 0.93 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox